Arrowstreet Capital Limited Partnership Boosts Stake in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Arrowstreet Capital Limited Partnership increased its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 7.1% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 13,756 shares of the life sciences company’s stock after buying an additional 913 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Integra LifeSciences were worth $312,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Nisa Investment Advisors LLC raised its stake in Integra LifeSciences by 599.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after acquiring an additional 2,800 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Integra LifeSciences by 33.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 19,755 shares of the life sciences company’s stock valued at $448,000 after acquiring an additional 4,967 shares during the last quarter. Nordea Investment Management AB increased its holdings in shares of Integra LifeSciences by 4.1% in the 4th quarter. Nordea Investment Management AB now owns 127,908 shares of the life sciences company’s stock worth $2,919,000 after buying an additional 5,032 shares during the last quarter. Choreo LLC raised its position in Integra LifeSciences by 29.9% during the fourth quarter. Choreo LLC now owns 22,274 shares of the life sciences company’s stock valued at $500,000 after purchasing an additional 5,123 shares in the last quarter. Finally, Empowered Funds LLC purchased a new position in shares of Integra LifeSciences during the 4th quarter valued at about $180,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on IART shares. Truist Financial cut their price target on shares of Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating for the company in a research report on Friday. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Monday, March 31st. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $22.71.

Integra LifeSciences Trading Down 2.5 %

NASDAQ IART opened at $16.99 on Monday. The stock has a market cap of $1.31 billion, a P/E ratio of -188.76, a P/E/G ratio of 0.73 and a beta of 1.24. The stock’s fifty day moving average price is $22.28 and its 200-day moving average price is $22.34. Integra LifeSciences Holdings Co. has a 12 month low of $15.95 and a 12 month high of $33.04. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business had revenue of $442.65 million during the quarter, compared to analyst estimates of $445.15 million. During the same quarter last year, the company earned $0.89 EPS. The company’s quarterly revenue was up 11.5% compared to the same quarter last year. As a group, equities analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.